SPACE-TIC: The Effects of Muscle Vibration on the Development of Spasticity and Neuroplasticity in a Post-stroke Population (Acute and Subacute Phases)

Sponsor
Centre Hospitalier Universitaire Dijon (Other)
Overall Status
Recruiting
CT.gov ID
NCT05315726
Collaborator
(none)
132
1
3
59.6
2.2

Study Details

Study Description

Brief Summary

Several studies have recently tested the use of muscle vibration for the rehabilitation of patients after a stroke. When applied in a repeated and focused manner, this vibration appears to promote the recovery of functional capacities through the mechanisms of neuromuscular plasticity. These results are encouraging, showing in particular a significant decrease in spasticity in post-stroke patients in the chronic phase (> 6 months after stroke), on the upper and/or lower limbs. However, very few studies have been done on this type of early intervention. Muscle vibration may therefore be an innovative therapy to complement the care that is currently offered in the acute and subacute phase of post-stroke rehabilitation.

Moreover, brain plasticity after a stroke is particularly high in the 3 months after the accident, but the vast majority of studies having evaluated the impact of vibration in a chronic phase (> 12 months post-stroke). It is likely, however, that the influence of vibration, particularly on brain plasticity, is increased in the acute or subacute phase (first 6 months). To date, the effect of vibration on spinal cord or cortical plasticity has not been quantified in the acute or subacute phase. This is why the second part of this project (phase 2) aims to systematically evaluate and quantify the neuroplastic and functional effects of post-stroke vibration in the early phase.

Phase 1 (duration 2 weeks) - Validation of a method for measuring spasticity (upper limb) with an isokinetic dynamometer 32 patients with ischemic and/or hemorrhagic stroke (> 3 months after stroke)

Phase 2 (duration 6 months): Use of this objective technique to measure the effect of a muscle vibration protocol to limit the onset of spasticity in a population of 100 patients following a stroke, in the acute or subacute phase (< 6 weeks post-stroke) in a randomized trial:

  • intervention group: usual rehabilitation + muscle vibrations

  • control group: usual rehabilitation + placebo vibrations

Condition or Disease Intervention/Treatment Phase
  • Other: Dynamometer
  • Other: Muscle vibrations
  • Other: Muscle vibrations
  • Other: Placebo muscle vibration
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
132 participants
Allocation:
Randomized
Intervention Model:
Sequential Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
The Effects of Muscle Vibration on the Development of Spasticity and Neuroplasticity in a Post-stroke Population (Acute and Subacute Phases)
Actual Study Start Date :
Jun 14, 2022
Anticipated Primary Completion Date :
Jun 1, 2027
Anticipated Study Completion Date :
Jun 1, 2027

Arms and Interventions

Arm Intervention/Treatment
Experimental: Pahse 1

Other: Dynamometer
Measurement of elbow/wrist spasticity

Other: Muscle vibrations
1 session of 10 minutes

Experimental: Phase 2: Intervention group

Other: Dynamometer
Measurement of elbow/wrist spasticity

Other: Muscle vibrations
3 times/week for 6 weeks

Active Comparator: Phase 2: control group

Other: Dynamometer
Measurement of elbow/wrist spasticity

Other: Placebo muscle vibration
3 times/week for 6 weeks

Outcome Measures

Primary Outcome Measures

  1. Phase 1: Joint angle (elbow of the limb contralateral to the brain injury) [at baseline]

    Elbow joint angle (elbow of the limb contralateral to the brain injury) at the onset of a spastic contraction (maximum intensity of resistance to mobilization) recorded by isokinetic dynamometer on a wheelchair during the initial visit

  2. Phase 2: Scoring wrist flexor muscle spasticity [at 6 weeks]

    Scoring of wrist flexor muscle spasticity (especially FCR) by isokinetic dynamometer (angle of onset), at the beginning of the study and at 6 weeks (end of intervention).

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
Phase 1:
  • Adult patient,

  • Medically stable on medical assessment, with no contraindications to stroke rehabilitation management management (no medical problems or acute intercurrent medical events),

  • Have had an ischemic and/or hemorrhagic stroke (> 3 months post-stroke), impacting the motor skills of the upper limbs,

  • 1 ≤ MAS < 4 on elbow flexors,

  • Having given oral consent.

Phase 2:
  • Adult patient,

  • Medically stable on medical evaluation, with no contraindications to stroke rehabilitation (no medical issues or acute intercurrent medical events),

  • With a first stroke < 6 weeks previously, confirmed by imaging,

  • Altered motor skills in the upper limb (contralateral to the lesion) (Fugl and Meyer score), particularly in the wrist and elbow flexors,

  • Requiring inpatient or outpatient hospitalization in a rehabilitation center,

  • Having given oral consent.

Exclusion Criteria:
  • Phases 1 and 2:

  • Significant pain on mobilization of the elbow or wrist (visual analog scale > 5/10),

  • Presence of other neurological, muscular or osteoarticular conditions altering the functioning of the upper limb,

  • Apparent wound, which may defer inclusion, or very fragile skin,

  • Significant cognitive impairment: inability to understand simple instructions or give consent of any kind (not included if: LAST scores < 5/7 in comprehension, and if YES/NO answers are unreliable),

  • Not covered by national health insurance,

  • Pregnant or breastfeeding,

  • Being under guardianship or curatorship.

  • Person subject to a measure of legal protection

Contacts and Locations

Locations

Site City State Country Postal Code
1 Chu Dijon Bourgogne Dijon France 21000

Sponsors and Collaborators

  • Centre Hospitalier Universitaire Dijon

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Centre Hospitalier Universitaire Dijon
ClinicalTrials.gov Identifier:
NCT05315726
Other Study ID Numbers:
  • JULLIAND AOIparaM 2021
First Posted:
Apr 7, 2022
Last Update Posted:
Jul 6, 2022
Last Verified:
Jun 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 6, 2022